Friendly Technology Data From Home To Healthcare Providers

Slides:

Advertisements

Similar presentations

Implementing Expanded Seasonal Influenza Meeting Healthcare and Other Settings.

Advertisements

Vaclav Kirsner, PhD, Founder CEO bioZhena Corporation (970) Transforming Female Reproductive Health.

1 Vol. 01. p Vol. 01. p Vol. 01. p.20.

1 Vol. 03. p Vol. 03. p Vol. 03. p.21.

1 Vol. 02. p Vol. 02. p Vol. 02. p.19.

1 Vol. 03. p Vol. 03. p Vol. 03. p.16.

1 Vol. 02. p Vol. 02. p Vol. 02. p.30.

1 Vol. 03. p Vol. 03. p Vol. 03. p.35.

1 Vol. 02. p Vol. 02. p Vol. 02. p.10.

1 Vol. 01. p Vol. 01. p Vol. 01. p.14.

BioZhena Corporation 5/13/ Private Placement Offering and/or Strategic Alliance Proposal bioZhena Corporation.

ECIV 301 Programming & Graphics Numerical Methods for Engineers Lecture 26 Regression Analysis-Chapter 17.

ECIV 301 Programming & Graphics Numerical Methods for Engineers Lecture 25 Regression Analysis-Chapter 17.

Vaclav Kirsner, PhD, Founder CEO bioZhena Corporation (970) Transforming Female Reproductive Health.

Marquette University trial confirmed Turin results – this time with non-baseline subjects (as in real life). R.J. Fehring and W.D. Schlaff, J. Nurse-Midwifery.

Ovulona TM A revolutionary women’s health product & technology platform Personal monitor of cervix uteri © bioZhena Corporation From teen age to menopause.

Catherine Y. Spong, M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development March 7, 2013 Research Issues in the Assessment.

Vaclav Kirsner, PhD, Founder CEO (970) Transforming Female Reproductive Health Management.

The multitude of repeatable measurable features of the cyclic pattern makes it possible to determine the boundaries of the fertile window for every individual.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Clinical Trial Design Issues Phill Price MD.

ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.

Vaclav Kirsner, PhD, Founder CEO

Folliculogenesis In Vivo™

Ann Intern Med. 2014;160(11): doi: /M Figure Legend:

J.C. Trussell, M.D., Allen R. Kunselman, M.A., Richard S. Legro, M.D.

What our FIV™ tech does for women and for family planning

A gender sensitive organization should meet the following criteria in its practices: First, the balance of women and men on the staff should include a.

Vaclav Kirsner, PhD, Founder

WELCOME 12/18/15 Town Hall Meeting.

“Next Generation of Connected Health”

Vaclav Kirsner, PhD, Founder

R.J. Fehring and W.D. Schlaff, J. Nurse-Midwifery 43 (2), 117, 1998

Technology Overview FOLLICULOGENESIS IN VIVO™

Startup version of the Ovulona cervical sensor has FDA clearance

Outcomes Important to Patients, Public and Practitioners - Key results

OvulonaTM in bioZhena pro forma financial summary

Technology Overview Revolutionary technology –

Organizational Culture in the Oncology Medical Home

FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles Scott J. Morin, Ashley W. Tiegs, Jason M.

Chester County Immunization Coalition Adult Vaccine Project 2017

Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study Jean Luc Pouly, François Olivennes, Nathalie.

Program Goals. The National Quality Strategy and You: How CMS Quality Measures Affect Policy and Practice.

S1 Science Planet Earth topic

IUD Specialist in Mesa - Embry Women’s Health

Ovulona TM A revolutionary women’s health product & technology platform Personal monitor of cervix uteri From teen age to menopause © bioZhena Corporation.

New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation Giovanna Sighinolfi,

#. shop now P1080P · /' '

Reproduction in plants

Time-related increase in urinary testosterone levels and stable semen analysis parameters after bariatric surgery in men Richard S. Legro, Allen R. Kunselman,

The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging Eriko Y. Fujii, M.D., Ph.D.,

“Defining both the problems and the solutions in healthcare has to be a partnership between professionals and the communities they serve. “ Jeremy Taylor.

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Ovulona TM A revolutionary women’s health product & technology platform Personal monitor of cervix uteri From teen age to menopause © bioZhena Corporation.

Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study Donald Tredway, M.D., Ph.D.,

Vaclav Kirsner, PhD, Founder

Ovulographic™ Technology

Place Your Name & Title Here

Web and Internet Search: What’s Next?

Ovulographic™ Technology

Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: Results of 4,062 intrauterine insemination.

(maturation of dominant follicle)

OvulonaTM detects delayed ovulation

Clinical prediction models

What our FIV™ tech does for women and for family planning

From patients’ Ovulona™ units to a physician’s Ovulograph™

OvulonaTM monitors the end-organ effect of all reproductive effectors by measuring bioelectronic admittance of the outer-cervix tissue OvulonaTM basic.

OvulonaTM predicts & detects ovulation

© The Author(s) Published by Science and Education Publishing.

Vaclav Kirsner, PhD, Founder

Polycystic Ovary Syndrome (PCOS)

Presentation transcript:

Friendly Technology Data From Home To Healthcare Providers Ovulographic™ Folliculogenesis In Vivo™ (FIV™) Data From Home To Healthcare Providers From patients’ Ovulona™ units to a physician’s Ovulograph™ – when needed Posterior Fornix Next generation telemetric embodiment for users’ convenience Folliculogenesis data correlated with auxiliary data (e.g. BBT) Importance of the topic: The quality of ovulation is strained in normal women - by Richard S. Legro, Human Reproduction, Vol.28, No.6 pp. 1446–1447, 2013 ‘Improve the methods and criteria used to assess ovulatory dysfunction’ http://imslp.org/images/7/78/PMLP85117-uso20080202-03-smetana-vltava_vbr.mp3